Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?

PTSD Clinical Trial

Official title:

Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00202709
• Other study ID #: SSHF-AUIR-1
• Status: Completed
• Phase: N/A
• First received: September 12, 2005
• Last updated: July 27, 2011
• Start date: May 2002
• Est. completion date: August 2003

Study information

• Verified date: September 2005
• Source: Sorlandet Hospital HF
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway:National Committee for Medical and Health Research Ethics
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out if Thought Field Therapy has effect on certain anxiety disorders; agoraphobia, social phobia, and post traumatic stress disorder (PTSD).

Description:

Thought Field Therapy is an alternative treatment method that has been shown, by casuistic reports, to give good results when applied for anxiety disorders. In this study 52 patients, with one or more of the diagnoses agoraphobia, social phobia and/or PTSD, where randomized to either treatment with TFT or a wait list. The treatment group all got treatment in one week. 2 1/2 months later both the treatment group and the control group were tested on the same items as before the treatment started. After this evaluation phase the control group got the same treatment as the treatment or study group. Both groups were evaluated 3 and 12 months after treatment, the study group also 6 months after treatment. 4 patients were omitted because they changed groups. The study were performed from May 2002 until June 2003.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: August 2003
• Est. primary completion date: August 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• One or more of the study diagnoses agoraphobia, social phobia and/or PTSD

Exclusion Criteria:

• Ongoing psychosis

• Ongoing serious drug problems

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Agoraphobia
• Anxiety Disorders
• PTSD
• Social Phobia

Intervention

Behavioral:
• Thought Field Therapy (TFT)
Treatment with TFT twice in one week

Locations

Country	Name	City	State
Norway	Sorlandet Hospital	Arendal

Sponsors (1)

Lead Sponsor	Collaborator
Sorlandet Hospital HF

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global symptom index (gsi) on the Symptom checklist 90 revised (SCL-90-R)		Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.	No
Secondary	Davidson Trauma Scale		Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.	No
Secondary	Liebowitz Social Anxiety Scale		Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.	No
Secondary	Hospital Anxiety and Depression Scale (HADS)		Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.	No
Secondary	Fear Questionnaire (FQ)		Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.	No
Secondary	Sheehan Disability Scale		Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.	No